Croda Healthcare, the pharma and nutritional division of UK company Croda Oleochemicals, has introduced a new "smart ingredients" package of lipid concentrates for the growing nutraceuticals market.
The marine and plant-based omega-3 and -6 polyunsaturated fatty acids provide high levels of DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid) and GLA (gamma-linoleic acid) which, in recent scientific studies, have been attributed to an improvement for children with cognitive problems.
Croda's product Incromega DHA500TG SR provides the required 500mg/g of DHA and up to 100mg/g of EPA. Crossential GLA TG40, a GLA concentrate, is also recommended to match the product administered.
Croda Healthcare is an operating division of Croda Oleochemicals, the UK-based speciality chemicals manufacturer. Globally Croda Oleochemicals had sales of £261 million (€413.4m) in 2001, and recorded a trading profit of £37.7 million. The oleochemicals division employs 1600 people, with sales and distribution coordinated by over 60 companies worldwide.